drugset / Trial / NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
Timeline
- Start
- 2023-09-12
- Primary completion
- 2024-07-11
- Completion
- 2024-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retatrutide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | drospirenone | Unknown | — | Oral |
| Subject | ethinyl estradiol | Small molecule | — | Oral |